# Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

> **NCT05567055** · PHASE2 · WITHDRAWN · sponsor: **Timothy Burns, MD, PHD**

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Capmatinib

## Key facts

- **NCT ID:** NCT05567055
- **Lead sponsor:** Timothy Burns, MD, PHD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10-03
- **Primary completion:** 2026-09
- **Final completion:** 2028-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05567055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05567055, "Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05567055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*